Sep 4, 2024
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
Jul 1, 2024
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Oncolytic Immunotherapy VET3-TGI for Solid Tumors
Feb 21, 2024
KaliVir Immunotherapeutics Appoints James M. Burke, M.D., as Chief Medical Officer
Jan 31, 2024
KaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Viruses
Oct 24, 2023
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Systemic Oncolytic Virus ASP1012 for Phase I Clinical Trials for Locally Advanced or Metastatic Solid Tumors
May 19, 2023
KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Superior Therapeutic Efficacy of VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
May 10, 2023
KaliVir Immunotherapeutics Appoints Viral Immunotherapy Researcher Grant McFadden, Ph.D., to its Board of Directors
May 3, 2023
KaliVir Immunotherapeutics Announces Presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Apr 17, 2023
KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Potent Therapeutic Activity for Oncolytic Therapy VET3-TGI at the American Association for Cancer Research (AACR) Annual Meeting
Dec 13, 2022
KaliVir Immunotherapeutics Establishes Clinical and Scientific Advisory Boards
Nov 10, 2022
KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting
Nov 1, 2022
KaliVir Appoints Industry Veteran Adina Pelusio as Senior Vice President of Clinical Operations to Lead Clinical Development Pipeline
Oct 24, 2022
KaliVir Immunotherapeutics to Present at 14th International Oncolytic Virotherapy Conference (IOVC)
Oct 5, 2022
KaliVir Immunotherapeutics to Present Data on its Novel Pre-Clinical Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) Annual Meeting
May 23, 2022
KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses
Mar 16, 2022
KaliVir Immunotherapeutics Closes Series A Financing
Nov 4, 2021
KaliVir Immunotherapeutics Strengthens Intellectual Property Position Through Issuance of Two U.S. Patents.
December 7, 2020
KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus.
2020
How Stephen Thorne and Helena Chaye are blending their talents to create Breakthrough cancer fighting therapies
June 17, 2021
KaliVir Immunotherapeutics appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors